BRD4 and breast cancer: In this study, we examined if a novel drug, namely, ITH-47, which is a potential BRD4 inhibitor, combined with an antimitotic compound, namely, ESE-15-ol, would synergistically inhibit the growth of tumorigenic MCF-7 and metastatic MDA-MB-231 breast cancer cell lines.